Menarini and Insilico Medicine announce new licensing agreement for solid tumor asset
Jan. 13, 2025
An exclusive licensing agreement with Insilico Medicine Inc. grants Menarini’s Stemline Therapeutics Inc. the global rights to develop and commercialize a preclinical small molecule for high unmet needs in oncology.